Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Imugene Limited (IUGNF)
OTHER OTC:IUGNF
Holding IUGNF?
Track your performance easily
IUGNF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.02 - $0.11
Previous Close$0.03
Volume55.00K
Average Volume (3M)131.25K
Market Cap
$203.50M
Enterprise Value$138.66M
Total Cash (Recent Filing)AU$99.89M
Total Debt (Recent Filing)AU$673.43K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Feb 26, 2025EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. Volume212,959
30 Day Avg. Volume131,249
Standard Deviation0.42
R-Squared0.22
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.42Price Target Upside1461.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Imugene Limited News
PremiumCompany Announcements
Imugene Limited Updates and Focus on Cancer Therapies
PremiumCompany Announcements
Imugene Limited Announces Director Change and Stock Holdings
PremiumCompany Announcements
Imugene Announces Board Changes Amid Cancer Therapy FocusPremiumCompany Announcements
Imugene Limited Advances Amidst AGM Vote Challenges
PremiumCompany Announcements
Imugene Limited: Leading Innovation in Cancer Treatment
PremiumCompany Announcements
Imugene Limited Begins Innovative Cancer Trial
PremiumCompany Announcements
Imugene Launches Phase 1b Trial in Australia
PremiumCompany Announcements
Imugene Achieves Milestone in Cancer Treatment TrialOptions Prices
Currently, No data available
---
Ownership Overview
7.22% Insiders
2.55% Mutual Funds
<0.01% Other Institutional Investors
87.37% Public Companies and
Individual Investors
IUGNF FAQ
What was Imugene Limited’s price range in the past 12 months?
Imugene Limited lowest stock price was $0.02 and its highest was $0.10 in the past 12 months.
What is Imugene Limited’s market cap?
Currently, no data Available
When is Imugene Limited’s upcoming earnings report date?
Imugene Limited’s upcoming earnings report date is Feb 26, 2025 which is in 96 days.
How were Imugene Limited’s earnings last quarter?
Imugene Limited released its earnings results on Aug 30, 2024. The company reported -$0.007 earnings per share for the quarter, the consensus estimate of -$0.007 by $0.
Is Imugene Limited overvalued?
According to Wall Street analysts Imugene Limited’s price is currently Undervalued.
Does Imugene Limited pay dividends?
Imugene Limited does not currently pay dividends.
What is Imugene Limited’s EPS estimate?
Imugene Limited’s EPS estimate is >-$0.01.
How many shares outstanding does Imugene Limited have?
Imugene Limited has 7,438,310,500 shares outstanding.
What happened to Imugene Limited’s price movement after its last earnings report?
Imugene Limited reported an EPS of -$0.007 in its last earnings report, expectations of -$0.007. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene Limited?
Currently, no hedge funds are holding shares in IUGNF
---
Imugene Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.42 (1461.34% Upside)
$0.42 (1461.34% Upside)
Blogger Sentiment
Bullish
IUGNF Sentiment 90%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.00%
12-Months-Change
Fundamentals
Return on Equity
-95.64%
Trailing 12-Months
Asset Growth
-22.92%
Trailing 12-Months
Company Description
Imugene Limited
Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.
---
IUGNF Stock 12 Month Forecast
Average Price Target
$0.42
▲(1461.34% Upside)
Technical Analysis
Best Analysts Covering IUGNF
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-48.77%
reiterated a buy rating 7 months ago
Copying John Hester's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -48.77% per trade.
---